Difficulties mastered are opportunities won.
— Winston Churchill

YY Wins Best Presentation Award

YY (Dr Hui Xin Ong) was awarded 'best presenter' at the I3Innovation in Inhalation Conference hosted by Dr David Lewis and team in the UK. The conference, brought together researchers from within the field and ran over two days at the Celtic Manor Resort in South Wales. The conference was a complete success and YY's talk outlining her recent advancements in cellular biology, drug transport and medical imaging resulted in her being awarded £500 for best speaker sponsored by Nanopharm Ltd.

 
Clockwise from top left: Prof David Ganderton OBE and YY; YY receives award; A/Prod Daniela Traini, YY and Prof Joy Conway.

Clockwise from top left: Prof David Ganderton OBE and YY; YY receives award; A/Prod Daniela Traini, YY and Prof Joy Conway.

 

YY is currently on a European Respiratory Society Fellowship working at Southampton University with Prof Joy Conway studying the transport of drugs in the respiratory tract using a number of advanced cell based and radiographic imaging techniques.

SPIRITUS: (6-14) A Monthly update from the Respiratory Technology team at the WIMR.

This is our June 2014 update of news from the Respitech group at the WIMR.

JUNE.jpg

This month, members of the group travelled to Germany to establish a new partnership with Evonik Industries. Daniela and Paul spent time at Evonik's site near Darmstadt for an Evonik-Woolcock strategic workshop that focussed on future directions that will result in expansion of technology and research in a number of exciting new areas. 

At the same time, the Australian Research Council announced the successful participants in the 2014 linkage grant scheme. The Respiratory Technology group were awarded a three years grant worth $482,738 for the development of inhaled vaccines. This project was one of the first initiatives developed via preliminary talks with Evonik at the end of 2013. Dr Windhab (Evonik) is the linkage partner along with CIs Young and Traini. The grant was entitled 'One for all and all for one- Engineering a drug delivery platform for DNA vaccines to the lung’
 
Earlier in the month Paul was interviewed by John Scott on 4BC radio's Health and Wellbeing Show discussing the issues with common lung diseases including asthma, chronic obstructive pulmonary disease and tuberculosis and how we can develop new approaches to targeting such diseases. This interview coincided with the launch of a new video and partnership focussing on TB with Pharmaxis Ltd.

Two papers were published this month by the group. The first was entitled 'On the thermal and evolved gas analysis of salbutamol sulphate' in the Journal of Thermal Analysis and Calorimetry. This paper is the first output resulting from a collaboration between Dr Fabio Sonvico at University of Technology Sydney and the RespiTech group at the Woolcock. The second paper was a review entitled 'An overview of biosimilars' published in the Journal and Proceedings of the Royal Society of New South Wales. John Chan was the first author of the article.

As usual we would like to welcome new members and say good by to old colleagues. This Month we say farewell to John Chan who has taken up a position as a Formulation Scientist & Project Manager at JHL Biotech in Taiwan. We wish John all the best and also congratulate him for his successful award of his PhD from the University of Sydney this month. Well done Dr Chan!

Partnership to develop inhalable vaccines

Vaccine

The Respiratory Technology team at the Woolcock Institute of Medical Research, in collaboration with Evonik Industries, have been awarded an Australian Research Council (ARC) linkage grant to develop a low-cost vaccination platform. The team will develop a new inhalation technology that can be used to deliver a multitude of DNA based vaccines via the inhalation route. This project is very exciting news and marks the start of a new industrial collaboration. The grant, entitled: ‘One for all and all for one- Engineering a drug delivery platform for DNA vaccines to the lung’, was awarded to A/Prof Traini, Young and Dr Windhab and will last for 3 years  The ARC support this grant via $482,738 of funding.

Paul Young, Daniela Traini and Norbert Windhab (Evonik) at Woolcock-Evonik strategic workshop in Germany, July 2014.

Paul Young, Daniela Traini and Norbert Windhab (Evonik) at Woolcock-Evonik strategic workshop in Germany, July 2014.

Partnership to Target Tuberculosis

The Woolcock has partnered with Pharmaxis, a medical device company with a high-payload inhaler, to develop novel approaches to treat Tuberculosis. Members of the Respiratory Technology and Respiratory and Environmental Epidemiology groups at the WIMR are working together with Pharmaxis to develop an inhalable therapy for TB to be used in developed and developing countries.

To learn more about our vision for treating TB you can watch the video by clicking on the image above or following the link: http://vimeo.com/respitech/targeting-tuberculosis

You can learn more about the Woolcock Institute of Medical Research,  clinics and research at www.woolcock.org.au. Learn more about the Respiratory Technology team at the Woolcock at www.RespiTech.org. And don't forget to like RespiTech at www.Facebook/RespiTech. and follow us on twitter 

SPIRITUS: (5-14) A Monthly update from the Respiratory Technology team at the WIMR

shutterstock_153975185.jpg

This is our May 2014 update of news from the Respitech group at the WIMR.

This month members of the group attended RDD 2014 in Puerto Rico. The location and science was exceptional and our group presented seven full conference papers (congratulations to Yang, Mehra, YY, Alaa, Eric, Michele and Mariateresa). The 4 page conference abstracts for each are available via the www.rddonline.com publications portal. Paul chaired an interesting session on 'Optimizing Nasal and Pulmonary Formulations' and Yang gave an excellent poster on the podium, discussing the impact of pMDI orifice geometry on electrostatics and aerosol performance.

Members of the RespiTech Team at RDD 2014

Back home, members of the group celebrated the installation of a new flow-cytometer which was the result of our campaign to 'Solve lung disease one cell at a time'. The installation of this facility was via a substantial financial contribution from a kind donor who supports the Woolcock's mission to be Leaders in Breathing and Sleep Research.

www.ecr2star.org received fresh material on the importance and meaning of research metrics. The website also received minor upgrades and the addition of a new archive page of previous articles. Paul discussed the importance of ecr2star at the University of Sydney's Research Bites and we encourage researchers of all ages to get involved!

As usual, we would like to welcome new members to the team. This month Angelo Granieri, from the University of Ferrara, Italy, joins us. Angelo will spend the next 4 months studying aerosol generation of non-newtonian fluids for targeting the upper respiratory tract. Welcome Angelo! Finally, we would like to congratulate Judy Loo for being first author on a paper in Biofouling (IF: 4;) entitled 'Non-cytotoxic silver nanoparticles-polyvinyl alcohol hydrogels with anti-biofilm activity: Designed as coatings for endotracheal tube materials' Good work!

SPIRITUS: (4-14) A Monthly update from the Respiratory Technology team at the WIMR.

April 2014.jpg

This is our April 2014 update of news from the Respitech group at the WIMR.

This month the group have been busy hosting guests, traveling interstate to present and participate in a number of events and preparing for the ISAM 2014 conference. Early on in the month, Prof Carsten Ehrhardt (on sabbatical from Trinity college Dublin) gave a presentation to the Institute. Carsten's sabbatical was relatively short as he left us at the end of April, however we now have a number of established collaborations in the area of nasal and pulmonary cell biology which we will continue to work in partnership over the coming years

Early on in the month, a press release regarding formulation development for the Orbital device, by the RespiTech team and Pharmaxis drew attention of local media and resulted in Paul undertaking a number of radio interviews with national broadcasters (you can learn more here).

RespiTech at TSANZ 2014

Members of the Team traveled to the Thoracic Society of Australia and New Zealand (TSANZ) annual meeting in Adelaide where Mehra, Paul and Dany gave three separate talks. Mehra talked about drug transport and the impact of diet on asthma, Paul gave a presentation on advances in treating ventilator associated pneumonia and Daniela gave a podium on repurposing drugs for treating respiratory diseases. The following week, the team were at the annual Drug Delivery Australia meeting in Melbourne (this year linked with the 5th FIP Pharmaceutical Sciences World Congress), where Dany gave a presentation on treating TB by inhalation and how the Orbital device may be the answer.

Also this month, both Paul and Daniela attended the 30th Rebecca Cooper dinner and awards ceremony in Sydney, where Paul collected a Rebecca Cooper Medical Research Grant for the Woolcock Team (Burgess, Oliver, Young) entitled 'Using electric cell-substrate impedance to explore the regulation of angiogenesis in asthma'

As always we welcome and say goodbye to guests and RespiTech Team members. In addition to Carsten's departure, we also say farewell to Wilco. Wilco has made fantastic progress over the past 9 months on 2 projects. One focused on enhancing uptake of poorly soluble drugs in the lung and on treating pulmonary haemorrhage. Wilco is now current travelling around New Zealand before returning to the Netherlands. You can follow Wilco's adventure as we post them on our Facebook page. We wish you well for your future career and you are always welcome back. We also welcome Sumit Arora. Sumit is a PhD student form India that has been awarded a prestigious Endeavour Scholarship to spend time at the Woolcock for 4 months. His work will focus on inhalable anti-fungals.

We would like to congratulate members of the team for recent publications. This month the group have had 4 papers accepted in a number of Journals. Firstly, the group have had a paper accepted in 'Pharm. Res.' with colleagues at Monash University. The paper titled 'Spray characteristics of solution based pressurised metered dose inhalers: effects of formulation and co-flow conditions' uses high-speed schlieren to derive time-resolved velocity, penetration and spreading angle measurements in pMDI spray plumes. The second research paper accepted this month was authored by Alaa Tulbah. The paper accepted in 'AAPS PharmSci Tech' describes 'Novel Simvastatin Inhalation Formulation and Characterisation' for the treatment of hyper-mucosal secretion in bronchiectasis. Additionally, two Review papers were accepted this month. Mehra and YY were corresponding authors on a paper entitled 'Across the pulmonary epithelial barrier: integration of physicochemical properties and human cell models to study pulmonary drug formulations' accepted in 'Pharmacology and Therapeutics, while Wing and Judy were the first two authors on a review entitled 'Recent advances in curcumin nano-formulation for cancer therapy' accepted in 'Expert Opinion on Drug Delivery'. Well done all!


Lastly, April saw the team announce the opening of registration and abstract submission for the 2014 ISAM-Woolcock Conference to be held in Sydney. You can find out more information at the following link (http://woolcock.org.au/isam2014)

 
CLICK THE LUNG TO GO TO THE ISAM 2014 WEBPAGE

CLICK THE LUNG TO GO TO THE ISAM 2014 WEBPAGE

 

ISAM-Woolcock 2014 online Registration and Abstract submissions open!

Click the lung to go to the ISAM 2014 Webpage

Click the lung to go to the ISAM 2014 Webpage

The International Society for Aerosols in Medicine and the Woolcock Institute of Medical Research are proud to announce that both online registration and abstract submission for the 2014 Conference and Workshop are now open.

You can submit an abstract and/or register online now at www.woolcock.org.au/isam2014
Just follow the abstract and registration tabs! Note, early Bird registrations are open until 24th August 2014.

The conference will be held at the WIMR Headquarters on 25-26 Sept 2014 in Sydney, Australia.


The Topics for this year focus on paediatric respiratory medicine and bioequivalence of Inhaled formulations. Highlights include:

  • Emerging therapies for paediatric diseases.
  • The impact of your formulation on PK
  • Regulatory hurdles for paediatric therapy
  • In vitro in vivo correlation challenges and formulation prediction
  • Current practice and state-of-the-art for treating lung disease in children
  • Methodological approaches for IVIVC
  • Podium presentations
  • Posters sessions
  • Hands on workshop
  • Roundtable discussions
  • Conference dinner
  • Social events and networking

Early bird prices are AUD $225, $325 and $435 for students, academics and industry attendees, respectively. If you are interested in being a sponsor please contact us at isam2014@woolcock.org.au

We look forward to seeing you in September

The ISAM-Woolcock Team

 

SPIRITUS: (3-14) A Monthly update from the Respiratory Technology team at the WIMR.

This is our March 2014 update of news from the Respitech group at the WIMR.

This month, the RespiTech team have been busy developing the upcoming joint ISAM-Woolock conference in September and were pleased to announce the Keynote speakers. The program is starting to come together with a number of invited speakers and the first call for abstracts is planned for the 1st week in April. 

Eric & Michele using the new JEOL desktop SEM

In the laboratory, the team have overseen the installation of a new scanning electron microscope. The bench-top SEM will significantly enhance the groups productivity as we can immediately screen particulate systems after production, allowing us to optimise engineering processes via informed decisions. Meanwhile, the group published a paper in Drug Development and Industrial Pharmacy focussed on aersosolisation of high-dose cohesive powders intended for the treatment of bronchiectasis. This is the second paper with Pharmaxis Ltd investigating the Orbital multi-breath inhaler.

As usual, we would like to congratulate members of the team for their successes. Dr Mehra Haghi was awarded a Humboldt fellowship. This highly prestigious fellowship will allow Mehra to spend a year overseas in Prof. Claus-Michael Lehr’s lab at the University of Saarbrücken in Germany. Mehra will use this opportunity to further develop her research in the area of advanced cell biology models of the lung and immunology. At the same time, Mehra was also awarded a Asthma Australia travel award. This will allow Mehra to further develop links with like minded researchers in the areas of respiratory science. 

Meanwhile, Paul and Daniela received Honorary Appointments as Adjunct Professors at the University of Technology Sydney (UTS). Daniela and Paul have a long history of collaboration with UTS academics and will continue to build on these collaborations via a number of projects and co-supervised students at the ithree institute (Cynthia Whitchurch) and Pharmacy (Fabio Sonvico). We would also like to congratulate Michele Pozzoli who has officially transferred from Masters to PhD candidature at UTS. Michelle is supervised by Fabio, Paul and Daniela and was also awarded a $1,000 Vice Chancellors travel grant this month. He will join members of the team at RDD in Puerto Rico in May.

Respitech group on the WIMR terrace - March 2013

As usual, we would like to welcome new members/visitors and say goodbye to friends. Dave Lewis and Gemma Keegan from Chiesi returned to the Uk after a successful visit. A number of projects are already underway and the visit resulted in a number of new exciting research paths. Meanwhile Prof Carsten Ehrhardt joins us on sabbatical from Trinity College Dublin. The team are working with Carsten to develop a number of projects in the areas of applied respiratory cell molecular biology with a focus on transporters. He will give a seminar at the Institute next month. Prof Warren Finlay also visited us this month from the University of Alberta. Warren is working with the group to further establish projects in the area of nasal drug delivery. Finally, we would like to welcome Tim Cornish and Valentina Trotta to the group. Tim is undertaking an engineering honours year in the area of nasal flow path simulation and deposition and Valentina is a Cotutelle PhD student between The University of Sydney and Ferrara Universty (Italy) working in the area of anti-oxidants and respiratory therapy.

ISAM-Woolcock 2014 Joint Conference and Workshop Keynote Speakers Announced

Download the information flyer here

Download the information flyer here

The International Society for Aerosols in Medicine and the Woolcock Institute of Medical Research are proud to announce the 2014 Conference and Workshop at the WIMR Headquarters on 25-26 Sept 2014 in Sydney, Australia. The Topics for this year focus on paediatric respiratory medicine & bioequivalence of Inhaled formulations. Highlights include:

  • Emerging therapies for paediatric diseases.
  • The impact of your formulation on PK
  • Regulatory hurdles for paediatric therapy
  • The in vitro in vivo correlation challenge; formulation prediction.
  • Current practice and state-of-the-art for treating lung disease in children
  • Methodological approaches for IVIVC
  • Podium presentations
  • Posters sessions
  • Hands on workshop
  • Roundtable discussions
  • Conference dinner
  • Social events and networking

Confirmed Keynote speakers

Prof. Peter R. Byron. E Claiborne Robins Professor and Chairman Department of Pharmaceutics. Virginia Commonwealth University.

Prof Mark Everard. Winthrop Professor/McCusker Chair in Paediatric Respiratory Medicine, School of Paediatrics and Child Health, The University of Western Australia.

The call for abstracts and early bird registration will open on the 1st April 1st 2014. To learn more about the conference please visit www.woolcock.org.au/isam2014

SPIRITUS: (2-14) A Monthly update from the Respiratory Technology team at the WIMR.

shutterstock_157364768 copy.jpg

This is our February 2014 update of news from the Respitech group at the WIMR.

February has been a successful month for the RespiTech group with a number of announcements, developments and new team members.

Firstly, the National Health and Medical Council of Australia awarded members of the team a $401,708 NHMRC Development Grant, entitled ‘CSI Sydney’, to develop a formulation that targets chronic sinus infection and conduct a number of first in human imaging studies using a sinus targeting device. The grant was awarded to CIs Paul Young, Daniela Traini (RespiTech, Woolcock & Sydney Medical School USyd), Greg King (Physiology, Woolcock & Sydney Medical School USyd), Dale Bailey (Northern Clinical School, Usyd) (Ramin Rohanizadeh, Pharmacy, USyd), Cynthia Whitchurch (iThree Institute, UTS) and is partnered with a local pharmaceutical company AFT. Both The story was picked up by the ABC National radio service and local radio. Both Paul and Greg discussed the problems associated with sinus infection on a number of interviews and talk-back shows.

The RespiTech team along with the Respiratory Cellular and Molecular Biology group were also successful in receiving a grant from the Rebecca L. Cooper Medical Research Foundation. The grant, worth $22,000 will be used to purchase a electric cell-substrate impedance sensing (ECIS) instrument for studying respiratory cell cultures.

There was more reason to celebrate when the Woolcock organised a morning tea to award one of the RespiTech postdocs, Wing Hin a $10,000 ECR grant. Wing will use this seed funding to develop his research on targeted respiratory cancer therapy. 

Meanwhile, John Chan had a paper accepted in Journal of Pharmaceutical Sciences entitled “A novel inhalable form of rifapentine” This work forms the basis of the groups ongoing TB targeting research program.

RespiTech members enjoyed a number of social events in February. The Italian contingent organised a farewell pizza dinner for ‘YY, the boss’ at Fratelli Fresh while Yang organised a second outing for beer, sushi and karaoke. YY will now spend the next 12 months in Southampton with Prof Joy Conway’s group establishing a collaboration in the area of medical imaging. She will keep us updated via a new blog.

As usual we like to introduce new members of RespiTech team and welcome visitors. Matteo Padroni joins us from Ferrara, Nadine Vermeiren from the Netherlands and Emelie Britt Linnea Land is a local grad student. Matteo is working in the area of antibiotic therapy, Nadine in aerosol particle formation mechanics and Emelie on the use of Spacer in emergency room treatment. Finally, we would like to welcome visitors Dr Dave Lewis and Dr Gemma Keegan. Dave and Gemma, are from Chiesi’s Innovation centre in the UK. Dave and his team have a long history of working with our group and their visit to Australia is to firm up the focus of a number of projects including our joint ARC Linkage program and co-supervision of PhD student Yang. Welcome!

RespiTech successful in securing funding for nasal drug targeting

shutterstock_166610216.jpg

Members of the RespiTech team and Lung Physiology group at the Woolcock Institute of Medical Research (WIMR) and the University of Sydney have been successful in securing a National Health and Medical Research Council (NHMRC) Development Grant. Associate Professors Paul Young, Daniela Traini and Greg King (WIMR), along with Prof Dale Baily (Central Clinical School), Dr Ramin Rohanizadehh (Pharmacy) and A/Prof Cynthia Whitchurch (UTS iThree Institute) have been awarded $401,708 to research and develop a series of technologies for targeting chronic sinus infection.

Chronic sinus infection (CSI) is prevalent and results in severe discomfort and pain for many Australians; yet, has no specific cure or effective treatment. Our multi-disciplinary research team and an Australian health and medical research company, (AFT Pharmaceuticals) have partnered to develop a novel device that specifically targets the sinuses in conjunction with a formulation capable for simultaneously removing mucus, dispersing biofilms and killing bacteria in the nasal cavities. The Project will commence in the first quarter of 2014 and will run for 2-years.

SPIRITUS: (JAN-14) A Monthly update from the Respiratory Technology team at the WIMR.

This is our January 2014 update of news from the Respitech group at the WIMR.

Jan 2014.jpg

The RespiTech Group celebrates a year of operation this month and look forward to an exciting year ahead. In January the group has been ramping up operations for 2014 and celebrating a number of new initiatives and successes.

Firstly, Wing-Hin Lee was awarded the Woolcock Institute’s inaugural Early Career Researcher Grant. Wing will use the $10,000 grant to establish his project proposal in the area of lung cancer targeting. The group also congratulates Mehra Haghi for receiving a Travel Grant from the Thoracic Society of Australia and New Zealand. Mehra will use the award travel to South Australia in April to attend the annual meeting and present her work.

As usual we would like to welcome new members to our group. Jasper Lamers and Mary Goud have joined us from the Netherlands as visiting researchers. Jasper will be working on projects within the field of patient compliance and ‘good inhaler device use’, while Mary will be working on advanced phosphodiesterase inhibitor therapies. We would also like to welcome Khanh Huynh to the group. Khanh is an Honours student from Engineering and will spend the next year with the group studying and optimising fluid flow paths through dry powder inhaler devices using in vitro and in silica models.

The group celebrated Chinese New Year this month, with members bringing a number of dishes to enjoy, including sushi, cupcakes and beef tendon jelly. The event was also accompanied by the celebration of John Chan’s successful PhD thesis submission. We also announced the successful completion and launch of the Woolcock Video, of which a number of the group were involved in making a success. You can find the Woolcock Video, Chinese New Year and other group social activities on our Facebook Page (www.Facebook.com/RespiTech).

Lastly, we would like to congratulate YY for publishing a first author paper in AAPS Journal entitled ‘Combined Inhaled Salbutamol and Mannitol Therapy for Mucus hyper-secretion in Pulmonary Diseases’. This study utilises a number of cell-based models and in vitro techniques to study the effect of combined β-2 agonist and mannitol formulations on cilia beat frequency, muscle contraction and drug absorption.

Welcome to the Woolcock!

Members of the RespiTech team have been working with the Woolcock to produce a short video that highlights the uniqueness of our institute. You can watch the video by clicking on the image above or following the link: http://vimeo.com/respitech/welcome-to-the-woolcock

You can learn more about the Woolcock Institute of Medical Research, our clinics and research at www.woolcock.org.au. Learn more about the Respiratory Technology team at the Woolcock at www.RespiTech.org. And don't forget to like RespiTech at www.Facebook/RespiTech.

Wing-Hin awarded The Woolcock's first ECR grant

Wing-Hin Lee

Wing-Hin Lee

Wing-Hin Lee has been awarded the inaugural Woolcock ECR grant. Wing will receive $10,000 as seed funding to develop a research program within the Respiratory Technology group. The seed funding will support his proposal, entitled ' Inhalable iron oxide nanoparticles for imaging and cancer therapy: from bench to bedside', to develop an advanced nano technology based lung cancer therapy. Wing was one of 6 early career researchers who presented at the Woolcock Think Tank in November 2013 and submitted a grant proposal. The Board of the Woolcock ranked these proposals and awarded Wing the seed funding grant. All the proposals were outstanding and the Research Committee will  work with all the ECRs to develop these projects into potential external funding proposals.



SPIRITUS: (12) A Monthly update from the Respiratory Technology team at the WIMR - end of year report and one year anniversary.

Dec.jpg

This is our December update of news from the Respitech group at the WIMR.

The Respiratory Technology Team at the Woolcock Institute of Medical Research celebrate their first year of operation. The group has achieved a lot in the past 12 months. We have grown since January and  have had 22 research personal come through our doors. We have published 28 peer reviewed articles, sourced funding for a number of projects and have established wider initiatives within the community. To highlight some of the achievements over the past year the group has prepared an annual report outlining some of the initiatives and key performance outcomes. The report that can be downloaded here. Importantly, the group has partaken in a number of social events including, cook-ups, the famous hot pot adventure, all-important pub trips and a harbour cruise. To learn more about the social side of RespiTech you can always like us on Facebook  - www.facebook.com/RespiTech

In December, members of our group travelled to Edinburgh to participate at the Drug Delivery to the Lungs Conference, DDL24. Jesslynn Ooi, John Chan and Judy Loo were nominated to speak at the prestigious Pat Burnell New investigator award session. Prior to DDL, the group participated in the first ECR2STAR workshop in London. The conference was a great success and the team will be involved in developing new and and exciting early career programs in the coming year.
John Chan received a series of awards this month, including the Royal Society of NSW scholarship and best speaker at the AFPS conference in Korea. Meanwhile, YY (Hui Xin Ong) was awarded her PhD at The University of Sydney. YY was awarded an European Respiratory Society Postdoctoral fellowship and will move to the UK in early 2014 to commence a clinical focussed research project with Prof Joy Conway’s group in the area of medical imaging.

RespiTech 2013 Report.

RespiTech 2013 Report.

Also of note this month, the group announced the ISAM/Woolcock 2014 Joint Conference and workshop to be hosted in Sydney in September. The theme of the conference and further details will be announced in January via the Woolcock and ISAM websites.

Lastly, we would like to congratulate members of the group for publishing 4 peer reviewed articles this month. John published a review with Daniela entitled ‘An update on the use of rifapentine for tuberculosis therapy’ in Expert Opinion on Drug Delivery. Mehra was the first author on a publication in Pharmaceutical Research entitled ‘In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers’. This article describes the establishment and validation of a modified Anderson Cascade impactor for study drug transport across lung epithelia. Jesslynn published two articles as first author.  Firstly, she published an education article entitled ‘Graphing software for medical writers in the Journal of Medical Writing. Secondly, she published an article in Pharmaceutical Research entitled ‘Isothermal Calorimetry: A predictive tool to model drug-propellant interactions in pressurized metered dose systems’. This later article focusses on realtime monitoring of phase transitions in pMDI systems.

The group has come a long way in 2013 and we thank all our supporters and followers. We wish everyone a prosperous 2014 and look forward to the year ahead.

Respiratory Technology @ the WIMR Congratulations Graduating Student

YY, Michele, Mariateresa & Eric

YY, Michele, Mariateresa & Eric

Hui Xin Ong (YY) was awarded the degree Doctor of Philosophy by the University of Sydney in an official graduation ceremony. YY started her PhD in 2010 in the Faculty of Pharmacy under the supervision of Paul Young, Daniela Traini (WIMR) and Mary Bebawy (UTS). YY submitted her thesis, entitled 'TRANSPORT MECHANISMS OF INHALED CIPROFLOXACIN FORMULATIONS ACROSS CALU-3 LUNG EPITHELIA' within 3 years of commencing. Dr YY has been employed at the Woolcock Institute of Medical Research (WIMR) since March 2013 as a Postdoctorate Researcher in Respiratory Technology. YY  has made an outstanding achievement as an early career researcher and has already published 7 research articles in high impact journals within her field, as well as a number of peer reviewed full conference papers. YY has been awarded a European Respiratory Society Postdoctoral fellowship and will move to the UK in early 2014 to commence a clinical focussed research project with Prof Joy Conway’s group in the area of medical imaging.

John Chan awarded best ECR talk at ECR2STAR 2013

John Chan receiving award from Dr David Lewis (Chiesi UK Ltd) with PhD supervisor A/Prof Daniela Traini

John Chan receiving award from Dr David Lewis (Chiesi UK Ltd) with PhD supervisor A/Prof Daniela Traini

John Chan was awarded best early career speaker during the ECR2STAR workshop and conference held in London this December. 60 early career researchers and established academics attended the conference to discuss opportunities and hints and tips for becoming a leader in academia and industry. In the afternoon 11 ECRs showcased their work. John’s received an award for his talk on targeting TB and received a certificate and £200.

Royal Society of NSW award for John Chan

John Chan

John Chan

John Chan has been awarded a scholarship from the Royal Society  of NSW acknowledging his outstanding achievements as a young researcher. John, a postgraduate researcher in the Respiratory Technology group at the Woolcock Institute and Sydney Medical School, will receive the award and give a presentation at the society's general meeting and a paper for the Society's Journal in the new year. The award consists of a certificate acknowledging achievement, a $500 prize and a complimentary year of membership to the Society. 

You can learn more about the society and award here

Woolcock & ISAM to host 2014 Joint Conference & Workshop in Sydney

ISAM_WIMR 2014_Bumper Sticker.jpg

ISAM-Woolcock Institute Joint Conference on “Translating Advances in Understanding Lung Disease into Innovative Inhaled Therapeutics”The Woolcock Institute in Sydney, Australia is leading advances in understanding the mechanisms of lung diseases at the cellular level; it also has a long history of treating patients and improving their compliance through education and training on use of inhalers.  In between these two ends of the research spectrum is the effort to translate the advances in basic science into innovative therapeutic products that will make a difference in these patients’ lives.  To this end, ISAM and its members at the Woolcock Institute are planning a joint conference focused on “Translating Advances in Understanding Lung Disease into Innovative Inhaled Therapeutics” scheduled for September 25-26, 2014 in Sydney, Australia.  Please check the ISAM  www.isam.org and Woolcock www.woolcock.org.au websites regularly for more updates.

SPIRITUS: (11) A Monthly update from the Respiratory Technology team at the WIMR

This is our November update of news from the Respitech group at the WIMR.

shutterstock_134750123.jpg

In November, the RespiTech group has participated in a number of events. Firstly, we were involved in the Woolcock ‘Think Tank’, a two day conference that highlights the institute’s research strengths and identifies strategic directions for future projects and collaborations. Judy Loo gave an excellent presentation on modified intubation tubes for reducing pneumonia infection in ICU patients and Wing-Hin participated in the Woolcock’s ECR Translational Research Grant, pitching a novel lung cancer therapy. Also, YY won a bottle of bubbly for being the most enthusiastic ECR participant!

The team participated in the annual Melbourne Cup celebrations at the Institute. Meanwhile, Dany Traveled to Italy to conduct a series lectures as Visiting Professor at the University of Ferrara, while Paul went to AAPS in San Antonio USA to establish a series of new collaborations.

Later in the month, the team participated in the Chancellor’s reception at the Woolcock to celebrate a series of Centres of Excellence, a Corporative Research Centre, and the Woolcock Advanced Microscopy Suite. Paul spoke about the new microscopy facilities which are now operational.

As usual we welcome and say goodbye to RespiTech members. This month we say goodbye to Amitabh Prakesh and Ningyi Xu. Amitabh completed his Hons thesis on cilia beat function and was awarded his degree at the end of November. Ningyi completed her Masters degree with the team in the area of pressurised metered dose inhaler droplet drying kinetics. We wish both all the best in their future career. 

We would like to congratulate Eric (Bing Zhu) for being awarded his PhD from the University of Sydney. Erics’s thesis is entitled “The influence of formulation variables on particles generated from solution based pressurised metered dose inhalers”. Eric will continue working with the group as a postdoctoral scientist within the field of aerosol generation.

We would also like to congratulate Alaa Tulbah and Yang Chen for giving excellent PhD presentations at the Woolcock’s Friday morning seminars.

Lastly, we would like to congratulate Yang and Eric for publishing two papers this month. Yang was the first author on a publication in ‘Pharmaceutical Research’ entitled ‘The influence of actuator materials and nozzle designs on electrostatic charge of pressurised metered dose inhaler (pMDI) formulations’ while Eric was the first author on a paper in ‘Colloids and Surfaces A’ entitled ‘The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: influence of ethanol concentration and intrinsic drug properties’. Both these publications focus on one of areas of interest of the group- pMDI technology, and the study of particle properties after aerosol generation.


Woolcock Think Tank 2013

Alaa and Yang give woodcock seminar

Chancellors reception